This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

(Hypertension. 1997;29:b8.)
© 1997 American Heart Association, Inc.

Awards

Arthur C. Corcoran Memorial Lecturer 1996

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Dr Frohlich is a Distinguished Scientist and Vice President for Academic Affairs at Alton Ochsner Medical Foundation in New Orleans, and also serves as the current Editor-in-Chief of the American Heart Association’s journal Hypertension. Over the course of his distinguished career, Dr Frohlich has made important clinical and fundamental laboratory investigative contributions on the pathophysiology of hypertensive disease and the clinical pharmacology of antihypertensive agents.

View larger version (114K): [in this window] [in a new window]   Edward D. Frohlich, MD

His studies on antihypertensive agents have been concerned with the systemic and regional hemodynamic effects of most of the drug classes introduced from the thiazide diuretics through ß-blockers, centrally active adrenergic inhibitors, angiotensin converting enzyme inhibitors, calcium antagonists, and angiotensin II receptor antagonists. These studies have ranged from clinically and laboratory-oriented work to the multicenter Veterans Administration Cooperative Studies. Dr Frohlich’s clinical cardiovascular studies have identified routine clinical laboratory studies as surrogates for early target organ involvement in hypertension: left atrial abnormality and plasma uric acid elevation for left ventricular hypertrophy (LVH) and nephrosclerosis. His early studies demonstrated different systemic hemodynamic characteristics for the severity stages of essential hypertension as well as for secondary forms of hypertension. Moreover, his laboratory was the first to introduce echocardiography for patients with hypertension and quantitative electromagnetic flowmetry and radiomicrospheres for the rat. Using these techniques, he described a close association of LVH myocardial alterations and systemic and regional hemodynamics in the spontaneously hypertensive rat (SHR) with the essential hypertensive patient.

More recently, he has extended his work to the kidney in which he . . . [Full Text of this Article]